제놀루션
Financials
Valuation Metrics
제놀루션's Market Cap is ₩334B. At end of 2025 it was ₩364B. Ranked #1966 of 2,410 in KR market (top 82%), #1233 of 1,631 on KOSDAQ (top 76%), #208 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 33.39B KRW | KR#1,966/2,410 Sec#208/231 |
| Revenue | 10.03B KRW | KR#2,282/2,410 Sec#178/231 |
| Net Income | -5.65B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 94.61B KRW | KR#1,824/2,410 Sec#144/231 |
| Net Assets | 68.83B KRW | KR#1,693/2,410 Sec#144/231 |
| Employees | 86 | KR#1,753/2,410 Sec#140/231 |
| Value | ||
| P/B | 0.49x | KR#842/2,410 Sec#35/231 |
| P/S | 3.33x | KR#2,043/2,410 Sec#128/231 |
| FCF Yield | -21.88% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -8.21% | KR#1,892/2,410 Sec#138/231 |
| ROA | -5.97% | KR#1,971/2,410 Sec#145/231 |
| Op. Margin | -74.15% | KR#2,264/2,410 Sec#166/231 |
| Revenue Growth | 14.42% | KR#709/2,410 Sec#69/231 |
| Financial Health | ||
| Debt Ratio | 37.46% | KR#736/2,410 Sec#89/231 |
| Total Debt | 9.00B KRW | KR#1,649/2,410 Sec#150/231 |
| FCF | -7.31B KRW | KR#1,603/2,410 Sec#135/231 |
| Cash | 18.65B KRW | KR#1,283/2,410 Sec#96/231 |
| Current Ratio | 1.29x | KR#1,405/2,410 Sec#147/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -20.37% | KR#1,211/2,410 Sec#85/231 |
| 1M Return | 18.45% | KR#76/2,410 Sec#4/231 |
| From 52W High | -24.35% | KR#300/2,410 Sec#18/231 |
| 1Y MDD | -54.02% | KR#1,134/2,410 Sec#93/231 |
| Trading | ||
| Volume | 24,168 shares | KR#1,043/2,410 Sec#106/231 |
| Trading Value | 41.6M KRW | KR#1,583/2,410 Sec#166/231 |
| Foreign Own. | 1.16% | KR#1,957/2,410 Sec#193/231 |
| Per Share | ||
| EPS | -294 KRW | KR—/2,410 Sec—/231 |
| BPS | 3,587 KRW | KR#1,753/2,410 Sec#129/231 |
Company Info
The company, established in 2006, commenced manufacturing biological products and was listed on KOSDAQ in 2020. It operates in two main sectors: precision medicine, selling nucleic acid extraction reagents and automated equipment, and green bio, developing animal pharmaceuticals and crop protection agents using RNA interference technology. In 2024, it received approval for Honeyguard-R Solution, the world's first gene therapy for honeybee Sacbrood disease. The company is further expanding its business through R&D for Nosema disease treatments and eco-friendly RNA pesticides. Genolution is headquartered in Gangseo-gu, Seoul Metropolitan City.